Free Trial Information
BioCentury | Mar 17, 2017
Financial News

eGenesis completes venture financing

...Ventures, Alta Partners , Alexandria Real Estate Equities, Heritage Provider Network, Berggruen Holdings North America, Uprising...
Read More
BioCentury | Mar 17, 2017
Finance

CRISPR pigs

...Ventures, Alta Partners , Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd., Uprising...
Read More
BioCentury | Mar 16, 2017
Financial News

eGenesis raises $38M series A

...Alta Partners , Alexandria Real Estate Equities, Heritage Provider Network, Berggruen Holdings North America Ltd., Uprising...
Read More
BioCentury | Dec 12, 2016
Clinical News

LYC-30397-EC: Ph II UPRISE started

Lycera began the double-blind, placebo-controlled, U.S. Phase II UPRISE trial to evaluate 25 mg oral LYC-30937-EC once daily for 12 weeks in about 30 patients. Lycera Corp. , Ann Arbor, Mich. Product: LYC-30937-Enteric Coated ( LYC-30937-EC , LYC-30937)...
Read More
BioCentury | Jan 11, 2010
Strategy

Mulling over Biogen Idec's Future

...discovered programs are no longer in development (see "Evolution of Biogen's Pipeline," A21) . Shareholder uprising...
...in-house R&D and the absence of a commercial product launch since 2004 provoked a shareholder uprising...
Read More
Items per page:
1 - 5 of 5
BioCentury | Mar 17, 2017
Financial News

eGenesis completes venture financing

...Ventures, Alta Partners , Alexandria Real Estate Equities, Heritage Provider Network, Berggruen Holdings North America, Uprising...
Read More
BioCentury | Mar 17, 2017
Finance

CRISPR pigs

...Ventures, Alta Partners , Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America Ltd., Uprising...
Read More
BioCentury | Mar 16, 2017
Financial News

eGenesis raises $38M series A

...Alta Partners , Alexandria Real Estate Equities, Heritage Provider Network, Berggruen Holdings North America Ltd., Uprising...
Read More
BioCentury | Dec 12, 2016
Clinical News

LYC-30397-EC: Ph II UPRISE started

Lycera began the double-blind, placebo-controlled, U.S. Phase II UPRISE trial to evaluate 25 mg oral LYC-30937-EC once daily for 12 weeks in about 30 patients. Lycera Corp. , Ann Arbor, Mich. Product: LYC-30937-Enteric Coated ( LYC-30937-EC , LYC-30937)...
Read More
BioCentury | Jan 11, 2010
Strategy

Mulling over Biogen Idec's Future

...discovered programs are no longer in development (see "Evolution of Biogen's Pipeline," A21) . Shareholder uprising...
...in-house R&D and the absence of a commercial product launch since 2004 provoked a shareholder uprising...
Read More
Items per page:
1 - 5 of 5